FOXP3 and prostate carcinoma: Consistent with our predictions, the percentage of CD3+Foxp3+ T cells was higher in TLO from advanced prostate carcinoma (22.83 ± 7.83%) and PIN samples (24.4 ± 28.56%), compared to their frequencies in TLO from intermediate (15.28 ± 6.52%, PIN vs intermediate: p = 0.0287) and evanescent carcinoma patients (15.42 ± 5.02%) (Figure 8E).